![](/img/cover-not-exists.png)
Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177 Lu-PSMA radioligand therapy
von Eyben, Finn Edler, Kulkarni, Harshad R., Baum, Richard P.Volume:
10
Year:
2020
Journal:
Theranostics
DOI:
10.7150/thno.44568
File:
PDF, 262 KB
2020